MAPT and Alzheimer disease: Therefore, future studies should include measurements of AD-pathology, such as CSF amyloid-β, amyloid PET, CSF phosphorylated tau, and tau PET, in order to verify that damages to olfactory structures are the direct expression of AD pathology.